Business Context and Reporting Period
Company: Bausch + Lomb Corporation (BLCO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: A global eye health company operating in three segments: Vision Care (contact lenses, OTC eye care), Pharmaceuticals (prescription eye medications), and Surgical (medical devices, IOLs). The Company is currently a subsidiary of Bausch Health Companies Inc. (BHC), which holds approximately 88% of outstanding shares, with a planned separation pending.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $1,281 | $1,196 | $3,696 | $3,511 |
| Operating Income | $95 | $43 | $1 | $75 |
| Net (Loss) Income | $(25) | $8 | $(294) | $(303) |
| Net Loss Attributable to B+L | $(28) | $4 | $(302) | $(314) |
| Diluted EPS | $(0.08) | $0.01 | $(0.85) | $(0.89) |
| Operating Cash Flow (9M) | $147 (2025) vs $210 (2024) | |||
| Total Debt (Principal) | $5,013 (as of Sept 30, 2025) | |||
| Cash & Equivalents | $310 (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 7% ($85M) year-over-year, driven by volume increases ($76M) and favorable foreign currency ($19M). Nine-month revenue grew 5% ($185M).
- Segment Performance:
- Vision Care: Revenue up 8% (Q3) and 6% (9M), driven by dry eye portfolio and contact lens volumes.
- Pharmaceuticals: Revenue up 8% (Q3) and 3% (9M), led by MIEBO growth, partially offset by pricing pressures and declines in U.S. generics.
- Surgical: Revenue up 4% (Q3) and 5% (9M), supported by premium IOL momentum and acquisitions, though impacted by the enVista IOL recall.
- Profitability: Operating income improved significantly in Q3 ($95M vs $43M) but collapsed for the nine-month period ($1M vs $75M) due to higher SG&A, R&D, and restructuring costs.
- Debt Refinancing: In June 2025, the Company refinanced its credit facilities, issuing a new $2.325B Term Facility (2031) and $800M Revolver (2030), and repaid prior 2027 maturities. This resulted in a $6M loss on extinguishment of debt.
- Acquisitions: Completed acquisitions of Whitecap Biosciences (Jan 2025), Elios Vision (Dec 2024), and Trukera Medical (July 2024). A pending acquisition of manufacturing assets in Mexico is expected to close in Q4 2025/Q1 2026.
Outlook, Risks, and Unusual Items
- Product Recall: A voluntary recall of certain enVista IOL products (March 2025) due to toxic anterior segment syndrome (TASS) impacted the Surgical segment. The Company has resumed full production and resupply.
- Separation from BHC: The Company remains a controlled subsidiary of BHC. The planned separation (Distribution or Sale) is subject to achieving targeted debt leverage ratios and regulatory approvals. No assurance is given that the separation will occur or on what timeline.
- Legal Proceedings:
- Antitrust: Ongoing multidistrict litigation regarding generic pharmaceutical pricing (BHC and affiliates are defendants; B+L was removed from one complaint but remains involved in related matters).
- Product Liability: Shower to Shower talc litigation remains pending, though the Company expects indemnification from Johnson & Johnson.
- Intellectual Property: Settlement reached with Dr. Reddy's regarding Lumify generic entry (June 2027); ongoing litigation with Somerset and Gland Pharma.
- Macroeconomic Risks: Exposure to U.S. tariffs, counter-tariffs, and global trade restrictions. The Company is monitoring the "One Big Beautiful Bill Act" and global minimum tax implementation.
- Guidance: The filing does not provide specific numerical financial guidance for the full year 2025. Management expects to remain in compliance with debt covenants.
Investor Verification Checklist
- Debt Covenants: Verify the Company's ability to meet the maximum first lien net leverage ratio (5.75:1.00 initially) required by the June 2030 Revolving Credit Facility.
- Separation Timeline: Monitor updates on the BHC separation plan, specifically the achievement of leverage targets and shareholder approvals.
- enVista Recall Impact: Assess the long-term financial and reputational impact of the enVista IOL recall on the Surgical segment's margins and market share.
- Rebate Pressures: Review the increasing gross-to-net pricing pressures (rebates rose to 39.6% of gross sales in Q3 2025) driven by dry eye products like XIIDRA and MIEBO.
- Acquisition Integration: Evaluate the integration progress and expected ROI from recent acquisitions (Whitecap, Elios, Trukera) and the pending Mexico facility purchase.